Citigroup Maintains Buy on GoodRx Holdings, Lowers Price Target to $3.5
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Daniel Grosslight maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and lowers the price target from $4.5 to $3.5.
Citigroup analyst Daniel Grosslight maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and lowers the price target from $4.5 to $3.5.